Ozanimod

Drug Profile

Ozanimod

Alternative Names: RPC-1063

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Celgene Corporation; Receptos
  • Class Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis; Ulcerative colitis
  • Phase II Crohn's disease

Most Recent Events

  • 27 Apr 2017 Celgene completes the phase II STEPSTONE trial in Crohn's disease in USA, Ukraine, Poland, Hungary, and Canada
  • 27 Apr 2017 Celgene plans a phase III trial for Crohn's disease in the end of 2017
  • 01 Feb 2017 Celgene completes the phase III SUNBEAM trial for Multiple sclerosis (Treatment-experienced) in USA, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Estonia, Georgia, Germany, Hungary, Latvia, Lithuania, Moldova, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom (NCT02294058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top